Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Teva Pharmaceutical, Samsung Bioepis expand biosimilars alliance with two FDA-approved US immunology commercialization rights
Licensing deal, biosimilars, autoimmune, commercialization, manufacturing - Read more

Kyorin Pharmaceutical, Edesa Biotech partner on Japan rights to paridiprubart for ARDS, $12M upfront, $140M total
Licensing deal, respiratory, antibody, milestone payments, royalties - Read more

Network Bio partners with Duke University to train AI on patient samples for drug target identification
Research collaboration, AI/ML, drug discovery, biomarkers, licensing deal - Read more

Laboratoires Pierre Fabre, XtalPi collaborate on AI-driven oncology drug discovery with undisclosed milestones
Research collaboration, oncology, rare disease, AI/ML, small molecule, milestone payments - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Vir Biotechnology's (elebsiran/tobevibart) combination meets primary endpoint in Ph3 trial for chronic hepatitis D
Combination therapy, infectious disease, antiviral, hepatitis D, RNA interference - Read more

Novo's (ziltivekimab) IL-6 inhibitor shows Ph3 potential in less severe cardiovascular and chronic kidney disease patients
Antibody, cardiovascular, IL-6 inhibitor, monoclonal antibody, chronic kidney disease - Read more

Faeth Therapeutics' Piktor (serabelisib + sapanisertib) hits 33% response rate in Ph2 advanced endometrial cancer trial
Small molecule, cancer, PI3K/mTOR inhibitor, endometrial cancer, combination therapy, ADC - Read more

Boehringer Ingelheim's (survodutide) glucagon/GLP-1 dual agonist passes Ph3 cardiovascular safety trial, paving way for 2027 obesity submission
Small molecule, metabolic, GLP-1/glucagon dual agonist, obesity, cardiovascular safety, MASH - Read more

Lisata's Marea MAR001 (ANGPTL4 antibody) achieves 72% triglyceride reduction in Ph2b hypertriglyceridemia study
Antibody, metabolic, monoclonal antibody, hypertriglyceridemia, ANGPTL4 target, obesity - Read more

Lilly's Foundayo (orforglipron) targets label expansion in obstructive sleep apnea after Ph3 Attain-OSA win
Small molecule, metabolic, GLP-1 receptor agonist, obstructive sleep apnea, obesity, cardiovascular - Read more

Valneva's Shigella4V2 (S4V2) meets primary endpoint in Ph2 trial, reducing shigellosis cases in adults
Vaccine, infectious disease, bioconjugate vaccine, shigellosis, pediatric population - Read more

J&J's Icotyde (icotrokinra) meets primary endpoint in Ph3 trial targeting IL-23 receptor for psoriatic arthritis
Small molecule, autoimmune, IL-23 receptor inhibitor, psoriatic arthritis, oral therapy - Read more

Amgen's Repatha (evolocumab) shows 20% lower heart attack rate vs. ezetimibe in real-world atherosclerotic cardiovascular disease study
Antibody, cardiovascular, monoclonal antibody, PCSK9 inhibitor, atherosclerotic cardiovascular disease, LDL cholesterol - Read more

Immunocore to initiate Ph2/3 trial of Kimmtrak (tebentafusp) plus brenetafusp combo targeting gp100 and PRAME in unresectable or metastatic uveal melanoma
Bispecific T-cell engager, cancer, uveal melanoma, combination therapy, gp100, PRAME - Read more

J&J's (pasritamig) and (JNJ-9401) bispecific combo shows Ph1 promise in metastatic castration-resistant prostate cancer
Antibody, cancer, bispecific antibody, prostate cancer, combination therapy, T-cell engagement - Read more

Cullinan Therapeutics' (velinotamig) BCMAxCD3 T cell engager shows complete renal responses in systemic lupus erythematosus Ph1b/2a data
Antibody, autoimmune, T cell engager, systemic lupus erythematosus, BCMA target, CD3 - Read more

CRISPR Therapeutics' (zugocabtagene geleucel) shows Ph1 promise targeting CD19 in refractory systemic sclerosis and rheumatologic autoimmune diseases
Cell therapy, autoimmune, CAR-T, allogeneic CAR-T, CD19, systemic sclerosis, systemic lupus erythematosus - Read more

Innovent Biologics' Sintbilo (tafolecimab) Ph3 meets primary endpoint as first-line monotherapy for hyperlipidemia
Antibody, cardiovascular, monoclonal antibody, hyperlipidemia, PCSK9, LDL-C reduction - Read more

Spruce Biosciences spins out Adrenyx Biosciences with up to $50M to advance CRHX-101 for congenital adrenal hyperplasia
Spinout, endocrinology, rare disease, antibody, equity investment - Read more

Jacquelin Forbes-Nixon Myeloma Fund launches with £15M ($20M) committed, targeting £30 ($40M) for myeloma cures
Myeloma, blood cancer, venture philanthropy, early-stage, diagnostics - Read more

Windward Bio plans $204M IPO to fund two China-licensed respiratory pipeline assets
Respiratory, antibody, clinical-stage, asthma, COPD - Read more

Delix Therapeutics raises $100M Series C, advancing non-hallucinatory psychedelic depression therapy
Neurological, small molecule, neuroplasticity, depression, clinical-stage - Read more

SRTD Biotech raises €31.5M ($35.1M) Seed funding to advance precision mRNA therapeutics pipeline
mRNA therapeutics, oncology, autoimmune, preclinical, AI-driven, platform technology - Read more

Moderna relocates UK commercial headquarters to London's King's Cross "Knowledge Quarter" innovation hub
mRNA platform, life sciences, operational - Read more

Argenx to acquire Unnatural Products for up to $1.145B to expand macrocyclic peptide drug pipeline
Macrocyclic peptide, autoimmune, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novartis, Ionis Pharmaceuticals' (pelacarsen) Ph3 trial fails to reduce major adverse cardiovascular events in cardiovascular disease
Antisense oligonucleotide, cardiovascular, small molecule, Lp(a) targeting, siRNA, coronary artery disease - Read more

Zura Bio's tibulizumab (IL-17A/BAFF inhibitor) fails Ph2 trial in hidradenitis suppurativa, discontinuing program
Antibody, autoimmune, monoclonal antibody, hidradenitis suppurativa, IL-17A inhibitor, BAFF inhibitor - Read more

FDA opens safety probe into Novartis' Zolgensma gene therapy over tumor formation risks
Gene therapy, rare disease, regulatory, safety - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here